血浆脂联素与胃癌

Plasma adiponectin and gastric cancer.

作者信息

Ishikawa Makoto, Kitayama Joji, Kazama Shinsuke, Hiramatsu Takeyuki, Hatano Kenji, Nagawa Hirokazu

机构信息

Department of Surgery, Division of Surgical Oncology, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.

出版信息

Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):466-72.

PMID:15701829

Abstract

BACKGROUND

Recently, increased body weight has been associated with an increased risk of cancers at multiple specific sites, including gastric cancer. Adiponectin is a peptide hormone secreted by adipose tissue, affecting the proliferation and insulin sensitivity of various types of cells. Moreover, the circulating level of adiponectin has been reported to be inversely related to body mass index.

METHODS

Fasting plasma levels of adiponectin were determined in 75 patients with gastric cancer and 52 healthy controls using an ELISA. In these patients, we analyzed the association between plasma adiponectin level and gastric cancer risk as well as various clinicopathologic characteristics.

RESULTS

Plasma adiponectin level was significantly lower in patients with gastric cancer than in healthy controls (9.1 +/- 6.2 versus 13.3 +/- 9.4 ng/mL, P < 0.01) and showed a significant modest inverse relation with the gastric cancer (odds ratio, 0.92; 95% confidence interval, 0.85-0.97; adjusted odds ratio, 0.89; 95% confidence interval, 0.84-0.95], although body mass index was not different. In addition, adiponectin level was extremely low in patients with upper gastric cancers (upper, 5.5 +/- 4.1 ng/mL; middle, 9.7 +/- 6.4 ng/mL; lower, 10.7 +/- 4.1 ng/mL; P = 0.012). Furthermore, adiponectin level tended to decrease as the tumor stage increased (stage I, 9.9 +/- 6.9 ng/mL; stage II, 8.7 +/- 5.5 ng/mL; stage III, 8.6 +/- 4.1 ng/mL; stage IV, 5.2 +/- 6.2 ng/mL; P = 0.34). Interestingly, in 32 patients with undifferentiated cancer, serum adiponectin showed a negative correlation with pathologic findings such as tumor size, depth of invasion, as well as tumor stage (P < 0.05), but no correlation in the remaining 43 patients with differentiated cancer.

CONCLUSIONS

Our results suggest that a low plasma adiponectin level is associated with an increased risk for gastric cancer and raise the possibility that adiponectin has a potential role in the progression of gastric cancer, especially in undifferentiated type cancers in the upper stomach.

摘要

背景

最近，体重增加与包括胃癌在内的多个特定部位癌症风险增加有关。脂联素是一种由脂肪组织分泌的肽类激素，影响各种类型细胞的增殖和胰岛素敏感性。此外，据报道脂联素的循环水平与体重指数呈负相关。

方法

采用酶联免疫吸附测定法（ELISA）测定75例胃癌患者和52例健康对照者的空腹血浆脂联素水平。在这些患者中，我们分析了血浆脂联素水平与胃癌风险以及各种临床病理特征之间的关联。

结果

胃癌患者的血浆脂联素水平显著低于健康对照者（9.1±6.2对13.3±9.4 ng/mL，P<0.01），并且与胃癌呈显著的适度负相关（比值比，0.92；95%置信区间，0.85 - 0.97；校正比值比，0.89；95%置信区间，0.84 - 0.95），尽管体重指数没有差异。此外，胃上部癌患者的脂联素水平极低（上部，5.5±4.1 ng/mL；中部，9.7±6.4 ng/mL；下部，10.7±4.1 ng/mL；P = 0.012）。此外，脂联素水平倾向于随着肿瘤分期增加而降低（I期，9.9±6.9 ng/mL；II期，8.7±5.5 ng/mL；III期，8.6±4.1 ng/mL；IV期，5.2±6.2 ng/mL；P = 0.34）。有趣的是，在32例未分化癌患者中，血清脂联素与肿瘤大小、浸润深度以及肿瘤分期等病理结果呈负相关（P<0.05），但在其余43例分化型癌患者中无相关性。